文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

免疫保护相关标志物在B族链球菌疫苗上市许可、政策决策和孕产妇免疫应用中的作用:世界卫生组织磋商的考量

The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.
PubMed 文献 · Vaccine · 2019-04-25

世界卫生组织磋商探讨了免疫保护相关标志物在B族链球菌(GBS)疫苗加速上市许可和孕产妇免疫应用中的潜在作用。由于随机对照试验评估疫苗对临床终点疗效所需样本量巨大,间接免疫学证据可作为上市许可的关键数据,并在上市后确认有效性。文章提出了支持监管和政策决策的优先活动。

要点

  • GBS疫苗对孕产妇免疫是预防早发性侵袭性疾病等全球公共卫生优先事项。
  • 传统随机对照试验因样本量要求构成疫苗可及性的重大障碍。
  • 基于免疫学数据的保护相关标志物可作为加速上市许可的关键证据。

核心结论

  • 免疫保护相关标志物可能加速GBS疫苗上市许可和广泛使用。
  • 基于免疫学数据的间接保护证据可作为关键上市许可数据,并需上市后确认有效性。

研究设计与样本

  • 基于世界卫生组织发起的磋商讨论,提出关键考量。

主要发现

  • 随机安慰剂对照试验评估疫苗对最相关临床终点的疗效所需样本量构成重大障碍。
  • 来自疫苗和血清流行病学研究的免疫学数据,辅以体外调理吞噬试验和动物模型数据,可考虑作为上市许可的关键数据。

临床怎么用

  • 可考虑使用免疫保护相关标志物支持GBS疫苗的加速上市许可和孕产妇免疫应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of a group B Streptococcus (GBS) vaccine for maternal immunization constitutes a global public health priority, to prevent GBS-associated early life invasive disease, stillbirth, premature birth, maternal sepsis, adverse neurodevelopmental consequences, and to reduce perinatal antibiotic use. Sample size requirements for the conduct of a randomized placebo-controlled trial to assess vaccine efficacy against the most relevant clinical endpoints, under conditions of appropriate ethical standards of care, constitute a significant obstacle on the pathway to vaccine availability. Alternatively, indirect evidence of protection based on immunologic data from vaccine and sero-epidemiological studies, complemented by data from opsonophagocytic in vitro assays and animal models, could be considered as pivotal data for licensure, with subsequent confirmation of effectiveness against disease outcomes in post-licensure evaluations. Based on discussions initiated by the World Health Organization we present key considerations about the potential role of correlates of protection towards an accelerated pathway for GBS vaccine licensure and wide scale use. Priority activities to support progress to regulatory and policy decision are outlined.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vekemans J, Crofts J, Baker CJ, et al. The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine. 2019. PMID: 31031031. doi:10.1016/j.vaccine.2019.04.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。